BMS-911557

BMS-911557 is a small molecule metabolite of BMS-906024, a pan-Notch signaling inhibitor developed by Bristol Myers Squibb. BMS-906024 acts as a gamma-secretase inhibitor (GSI), designed to prevent the proteolytic processing of Notch receptors (Notch 1-4), which is required for the release of the Notch intracellular domain (NICD) and subsequent transcriptional activation of target genes involved in cell proliferation and survival. BMS-911557 is primarily identified and monitored in clinical pharmacokinetic studies to evaluate the metabolic clearance and systemic exposure of the parent compound in patients with advanced solid tumors or T-cell acute lymphoblastic leukemia. While the parent drug BMS-906024 reached Phase 1 clinical evaluation, its development has since been discontinued.